Türk Uğur Önsel

Profile Picture
Profile URL
https://hdl.handle.net/20.500.14365/7489
Name Variants
Önsel Türk, Uǧur
Turk, U. O.
Türk, Ugur Önsel
Turk, Ugur Onsel
Türk, Ug̈ur
Job Title
Email Address
Main Affiliation
09. Faculty of Medicine
Status
Former Staff
Website
ORCID ID
https://orcid.org/0000-0001-6348-6616 View this author’s ORCID profile
Scopus Author ID
12774004400
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID

Sustainable Development Goals

NO POVERTY1
NO POVERTY
0
Research Products
ZERO HUNGER2
ZERO HUNGER
0
Research Products
GOOD HEALTH AND WELL-BEING3
GOOD HEALTH AND WELL-BEING
3
Research Products
QUALITY EDUCATION4
QUALITY EDUCATION
0
Research Products
GENDER EQUALITY5
GENDER EQUALITY
0
Research Products
CLEAN WATER AND SANITATION6
CLEAN WATER AND SANITATION
0
Research Products
AFFORDABLE AND CLEAN ENERGY7
AFFORDABLE AND CLEAN ENERGY
0
Research Products
DECENT WORK AND ECONOMIC GROWTH8
DECENT WORK AND ECONOMIC GROWTH
0
Research Products
INDUSTRY, INNOVATION AND INFRASTRUCTURE9
INDUSTRY, INNOVATION AND INFRASTRUCTURE
0
Research Products
REDUCED INEQUALITIES10
REDUCED INEQUALITIES
0
Research Products
SUSTAINABLE CITIES AND COMMUNITIES11
SUSTAINABLE CITIES AND COMMUNITIES
0
Research Products
RESPONSIBLE CONSUMPTION AND PRODUCTION12
RESPONSIBLE CONSUMPTION AND PRODUCTION
0
Research Products
CLIMATE ACTION13
CLIMATE ACTION
0
Research Products
LIFE BELOW WATER14
LIFE BELOW WATER
0
Research Products
LIFE ON LAND15
LIFE ON LAND
0
Research Products
PEACE, JUSTICE AND STRONG INSTITUTIONS16
PEACE, JUSTICE AND STRONG INSTITUTIONS
0
Research Products
PARTNERSHIPS FOR THE GOALS17
PARTNERSHIPS FOR THE GOALS
0
Research Products
Documents

72

Citations

850

h-index

16

Go to Scopus profile
This researcher does not have a WoS ID.
Scholarly Output

14

Articles

6

Views / Downloads

49/114

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

22

Scopus Citation Count

25

Patents

0

Projects

0

WoS Citations per Publication

1.57

Scopus Citations per Publication

1.79

Open Access Source

6

Supervised Theses

0

JournalCount
Anatolıan Journal of Cardıology5
Turk Kardıyolojı Dernegı Arsıvı-Archıves of the Turkısh Socıety of Cardıology3
Turk Kardiyoloji Dernegi Arsivi2
Türk Kardiyoloji Derneği Arşivi1
Journal of Electrocardıology1
Current Page: 1 / 2

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2021 - 202614
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 10 of 14
  • Thumbnail Image
    Article
    New Oral AntiCoagulants Use in Renal Disease and AF (NOACURE-AF) Where do We Stand?: An Expert Consensus View Using the Delphi Method
    (2021-07-02) Turk, Ugur Onsel; Alioglu, Emin; Ecder, Tevfik; Erdinler, Izzet Celal; Ok, Ercan; Ozluk, Ozlem Arican; Arıcı, Mustafa
    -
  • Thumbnail Image
    Letter
  • Thumbnail Image
    Conference Object
    Characteristics of Patients With Atrial Fibrillation on Edoxaban Treatment in Turkey: Baseline Data From Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (etaf-Tr) Study
    (Kare Publ, 2022) Turk, Ugur Onsel; Uguz, Berat; Inci, Sinan; Dost, Sahin; Tuluce, Kamil; Totan, Sahin; Erturk, Emre
    [Abstract Not Available]
  • Thumbnail Image
    Article
    Citation - WoS: 8
    Citation - Scopus: 7
    Evaluation of Demographic and Clinical Characteristics of Female Patients Presenting With Minoca and Differences Between Male Patients: a Subgroup Analysis of Minoca-Tr Registry
    (Kare Publ, 2022-01-06) Gok, Gulay; Coner, Ali; Cinar, Tufan; Kilic, Salih; Yenercag, Mustafa; Oz, Ahmet; Ekmekci, Cenk; Türk, Uğur Önsel; Zoghi, Mehdi; Ergene, Asim Oktay
    Objective: Although the prevalence and rate of myocardial infarction with non-obstructive coronary arteries (MINOCA) are higher in women than in men in previous cohorts, potential demographic and clinical differences between women who are diagnosed with MINOCA versus myocardial infarction with obstructive coronary arteries (MIOCA) have not been studied till date. In this study, we aimed to document these characteristics and to compare them between female patients with MINOCA and MIOCA. Methods: The study was a subgroup analysis of the MINO-CA-TR study. The study was a multi-center, observational cohort study that was conducted in Turkey between March 2018 and October 2018. In this study, 477 (29.3%) female patients who had been diagnosed with acute myocardial infarction were evaluated. Results: Of these women, 49 (10.3%) were diagnosed with MINOCA (mean age 58.9 +/- 12.9 years) and 428 (89.7%) had a final diagnosis of MIOCA (mean age 67.4 +/- 11.8 years). The prevalence of hypertension, hyperlipidemia, and diabetes mellitus was significantly lower in the MINOCA group than in the MIOCA group. In addition, the MINOCA group had higher rates of recent flu history and non-ST elevation myocardial infarction (NSTEMI) presentation than the MIOCA group. There were significant clinical differences in patients with MINOCA in terms of sex. The female patients were older, had higher systolic blood pressures, and lower hemoglobin levels than male patients. Conclusion: The study revealed that the prevalence of traditional coronary artery disease risk factors was lower in female patients with MINOCA than in those who had final diagnosis of MIOCA.
  • Thumbnail Image
    Article
    Citation - WoS: 13
    Citation - Scopus: 14
    Real-World Data on Empagliflozin and Dapagliflozin Use in Patients With Heart Failure: the Red-Heart Study
    (Wiley Periodicals, Inc, 2024-09-28) Kocabaş, Umut; Ergin, Işıl; Yavuz, Veysel; Altın, Cihan; Kaplan, Mehmet; Oztekin, Guelsuem Meral Yilmaz; Dogdus, Mustafa; Turk, Ugur Onsel; Yılmaz Öztekin, Gülsüm Meral
    Aims: We aimed to determine the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and to identify clinical factors associated with their use in patients with heart failure (HF) in a real-life setting. Methods: Real-world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED-HEART study is a multicentre, cross-sectional and observational study that included HF patients in the outpatient setting regardless of ejection fraction from 19 cardiology centres between August 2023 and December 2023. Results: The study population consisted of 1923 patients with HF, predominantly men (61.2%), with a median age of 66 (range: 19-101) years. Overall, 925 patients (48.1%) were receiving SGLT2is. Among the study population, 22.1% had HF with preserved ejection fraction, 21.5% had HF with mildly reduced ejection fraction, 56.4% had HF with reduced ejection fraction and the use of SGLT2is was 42.0%, 47.9% and 50.6% in each group, respectively (P = 0.012). The use of SGLT2is was 76.6% in patients with HF and diabetes, 19.8% in patients with HF and chronic kidney disease and 26.8% in patients without diabetes and chronic kidney disease (P < 0.001). Higher education level [odds ratio (OR): 1.80; 95% confidence interval (CI): 1.06-3.05; P = 0.027], higher household income (OR: 3.46; 95% CI: 1.27-9.42; P = 0.015), New York Heart Association functional class IV (OR: 2.72; 95% CI: 1.16-6.35; P = 0.021), diabetes (OR: 9.42; 95% CI: 6.72-13.20; P < 0.001), the use of angiotensin receptor-neprilysin inhibitors (ARNis) (OR: 4.09; 95% CI: 2.39-7.01; P < 0.001), the use of mineralocorticoid receptor antagonists (MRAs) (OR: 2.02; 95% CI: 1.49-2.75; P < 0.001), the use of loop diuretics (OR: 1.62; 95% CI: 1.18-2.22; P = 0.003) and the use of thiazide diuretics (OR: 1.72; 95% CI: 1.30-2.29; P < 0.001) were independently associated with the use of SGLT2is. Conversely, atrial fibrillation (OR: 0.63; 95% CI: 0.45-0.88; P = 0.008), chronic kidney disease (OR: 0.53; 95% CI: 0.37-0.76; P = 0.001), the use of dihydropyridine calcium channel blockers (OR: 0.68; 95% CI: 0.48-0.98; P = 0.042) and the use of statins (OR: 0.67; 95% CI: 0.49-0.91; P = 0.010) were independently associated with the non-use of SGLT2is. Conclusions: The RED-HEART study provided comprehensive real-world data about implementing SGLT2is in patients with HF. These results suggest that there is a need for organized action and close collaboration between healthcare providers to improve the implementation of SGLT2is, especially in patients with HF with preserved ejection fraction and chronic kidney disease.
  • Thumbnail Image
    Conference Object
    Arrhythmia/Electrophysiology/Pacemaker/CRT-ICD
    (Kare Publ, 2022) Boyuk, Ferit; Caliskan, Serhat; Kocabas, Umut; Cakmak, Ender Ozgun; Ozpelit, Ebru; Kasap, Mithat; Türk, Uğur Önsel
    [Abstract Not Available]
  • Thumbnail Image
    Review
    Citation - Scopus: 1
    New Oral Anticoagulants Use in Renal Disease and Af (noacure-Af) - Where Do We Stand?: an Expert Consensus View Using the Delphi Method
    (Turkish Society of Cardiology, 2021-07-02) Arici M.; Ecder T.; Erdinler I.; Ok E.; Özlük Ö.A.; Türk U.Ö.; Alio?lu E.; Arici, Mustafa; Erdinler, Izzet; Özlük, Özlem Arican; Ecder, Tevfik; Türk, Uǧur Önsel; Ok, Ercan; Alioǧlu, Emin
    [No abstract available]
  • Thumbnail Image
    Conference Object
    Characteristics of Patients With Atrial Fibrillation on Edoxaban Treatment in Turkey: Does Health Provider Type Matter? a Report From Etaf-Tr Study
    (Kare Publ, 2022) Kocabas, Umut; Demirci, Gokhan; Yagmur, Burcu; Saricam, Ersin; Mammadli, Anar; Kasap, Mithat; Turk, Ugur Onsel
    [Abstract Not Available]
  • Thumbnail Image
    Conference Object
    How Did the Population Characteristics of Engage-Af Trial Transcribed Real Life Conditions in Turkey: an External Validation Test With Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (etna)
    (Kare Publ, 2022) Baris, Veysel Ozgur; Erturk, Emre; Cetin, Nurullah; Bakir, Eren Ozan; Elcik, Deniz; Totan, Sahin; Turk, Ugur Onsel
    [Abstract Not Available]
  • Thumbnail Image
    Article
    Baseline Clinical Characteristics of Patients from the Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in TüRkiye Study
    (Kare Publ, 2026) Yavuz, Veysel; Turk, Ugur Onsel; Arslan, Ugur; Kocabas, Umut; Akgun, Didar Elif; Coner, Ali; Kurşun, Mustafa; Uguz, Berat
    Objective: A post-authorization safety study with a prospective design focusing on the safety of edoxaban treatment in Türkiye has not yet been conducted. The Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in TüRkiye (ETAF-TR) study was designed to evaluate the safety and effectiveness of edoxaban treatment in atrial fibrillation (AF). The baseline results of the ETAF-TR study describe the demographic, clinical, and laboratory characteristics of the study population. Method: The ETAF-TR study (NCT04594915) is a prospective, national, multicenter, observational, post-authorization safety study conducted in 50 outpatient cardiology clinics. Results: Overall, 1,053 patients with AFtreated with edoxaban forstroke prevention were enrolled in the study between August 2020 and May 2022. The mean age of the study population was 70.1 +/- 11.3 years, and 59.0% of the patients were female. Mean CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >= 75 years, Diabetes, Stroke/TIA/thromboembolism, Vascular disease, Age 65-74 years, Sex category) and HAS-BLED scores (Hypertension, Abnormal renal/ liver function, Stroke, Bleeding history/predisposition, Labile INR, Elderly, Drugs/alcohol) were 3.5 and 1.6, respectively. Of the 1,053 patients, 843 (80.1%) received standard-dose edoxaban and 210 (19.9%) received reduced-dose edoxaban. Of the 1,053 patients, 38 (3.6%) had off-label use of edoxaban therapy. Among the remaining 1,015 patients, 834 (82.2%) received an appropriate dose of edoxaban and 181 (17.8%) received an inappropriate dose of edoxaban according to the Summary of Product Characteristics (SmPC) criteria. Conclusion: Edoxaban has been used in a wide spectrum of patients with AF in daily routine practice, with good overall adherence to the SmPC. As the largest national pharmacovigilance study to date, the ETAF-TR study will provide detailed insight into the safety of edoxaban treatment.